SCHEMBL1835536

SCHEMBL1835536

CCCCCCCOCC(O)COCCCCCCC

nearest known ligand 0.80

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.80
HTT P42858 2/20 0.77
LPAR5 Q9H1C0 4/20 0.70
SPHK1 Q9NYA1 1/20 0.63
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2C19 P33261 1/20 0.54
MEN1 O00255 1/20 0.52
THRB P10828 1/20 0.52
KMT2A Q03164 1/20 0.52
MAPT P10636 1/20 0.52
LPAR1 Q92633 7/20 0.50
LPAR3 Q9UBY5 7/20 0.50
LPAR2 Q9HBW0 4/20 0.50
LPAR6 P43657 3/20 0.50
LPAR4 Q99677 3/20 0.50
HSD17B10 Q99714 1/20 0.50
PLA2G2C Q5R387 2/20 0.49
CES2 O00748 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1834847 1.00 USP2 (0.80) USP2HTTLPAR5SPHK1CYP1A2
SCHEMBL2996593 1.00 USP2 (0.80) USP2HTTLPAR5SPHK1CYP1A2
SCHEMBL10607854 1.00 USP2 (0.80) USP2HTTLPAR5SPHK1CYP1A2
SCHEMBL10566561 1.00 USP2 (0.80) USP2HTTLPAR5SPHK1CYP1A2
SCHEMBL10605202 1.00 USP2 (0.80) USP2HTTLPAR5SPHK1CYP1A2
SCHEMBL8527626 1.00 USP2 (0.80) USP2HTTLPAR5SPHK1CYP1A2
SCHEMBL9117095 1.00 USP2 (0.80) USP2HTTLPAR5SPHK1CYP1A2
SCHEMBL251104 1.00 USP2 (0.80) USP2HTTLPAR5SPHK1CYP1A2
SCHEMBL2853658 1.00 USP2 (0.80) USP2HTTLPAR5SPHK1CYP1A2
SCHEMBL28914358 1.00 USP2 (0.80) USP2HTTLPAR5SPHK1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829229-B2 Polyol ethers and process for making them DOW GLOBAL TECHNOLOGIES LLC (US) 2014-09-09 US disclosed
EP-2318346-B1 POLYOL ETHERS AND PROCESS FOR MAKING THEM DOW GLOBAL TECHNOLOGIES LLC (US) 2013-11-20 EP disclosed
EP-2318346-A1 POLYOL ETHERS AND PROCESS FOR MAKING THEM Dow Global Technologies LLC (US) 2011-05-11 EP disclosed
WO-2010027663-A1 POLYOL ETHERS AND PROCESS FOR MAKING THEM DOW GLOBAL TECHNOLOGIES INC. (US) 2010-03-11 WO disclosed
US-20100048940-A1 reductive etherification of a polyol with an aldehyde or ketone using a hydrogenation catalyt; resulting compounds have use as solvents, surfactants, degreasers, wetting agents, emulsifying agents, lubricants, and intermediates for surfactants; polyols can be from renewable raw materials DOW GLOBAL TECHNOLOGIES LLC 2010-02-25 US disclosed
EP-0624563-A1 Glycerin derivatives and process for producing the same KAO CORPORATION (JP) 1994-11-17 EP disclosed
EP-0138558-B1 PHOSPHOLIPIDS AND THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 1989-07-19 EP disclosed
US-4775758-A Phospholipids TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1988-10-04 US disclosed
EP-0138558-A2 Phospholipids and their production and use Takeda Chemical Industries, Ltd. (JP) 1985-04-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048940-A1 reductive etherification of a polyol with an aldehyde or ketone using a hydrogenation catalyt; resulting compounds have use as solvents, surfactants, degreasers, wetting agents, emulsifying agents, lubricants, and intermediates for surfactants; polyols can be from renewable raw materials RNF114, USP14, USP13 USP2 70/4885HTT 147/4885LPAR5 1726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.